At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
pemetrexeddrug
Likely dose
pemetrexed 900 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating pemetrexed for Ovarian Cancer and Peritoneal Cancer. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The primary purpose of this trial is to estimate the drug effect on tumors in patients with ovarian or primary peritoneal cancers. Patients will receive Pemetrexed every 21 days until disease progression or unacceptable toxicity. This medication will be given over 10 minutes and may be administered intravenously (IV), through a vein in your arm. Vitamin supplementation is a required part of this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsGynecologic Oncology Group
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
First PostedApr 2007
Primary CompletionOct 2007
Study CompletionMay 2008
TodayJul 2026
First PostedApr 18, 2007
Enrollment StartSep 1, 2004
Primary CompletionOct 1, 2007
Study CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.2 years ago
Interventions
pemetrexeddrug
900 mg/m2, intravenous (IV), every 21 days, until disease progression